WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15 th , at 9:00 AM ET. A live webcast of the panel... Read More

Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis Appointed Dr. Simon Cooper as Chief Medical Officer Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027 WALTHAM,... Read More

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all... Read More

WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March. 3/6/24 9:10 AM ET GI/Microbiome Panel Discussion at the TD Cowen 44 th Annual Health Care Conference 10:30 AM ET Fireside Chat at... Read More

Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC) Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC GARNET phase 2 trial of MORF-057 in Crohn’s disease (CD) expected to begin enrolling in the first half of 2024 Ended 2023 with $704.3 million in cash and equivalents; cash runway into second half of 2027 WALTHAM, Mass., Feb. 22, 2024 (GLOBE... Read More

Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., Chief Executive Officer of Morphic, has returned in full capacity from a... Read More

WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the upcoming Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference. Jefferies London Healthcare Conference Fireside Chat Date:... Read More

Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023 Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027 WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic... Read More

WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The... Read More

WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is expected to return to his role as Chief Executive Officer after he recovers. In the interim, Morphic’s executive team, led by Dr. Bruce Rogers, President and Dr. Marc Schegerin,... Read More

Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures Clinical improvement consistently seen across key measures at week 12, mMCS response of 45.7% and endoscopic improvement of 25.7% MORF-057 well tolerated with no safety signals observed PK/PD confirm results seen in healthy volunteer studies, with median RO >99% and saturation... Read More

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Marc Schegerin, MD, COO & CFO, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 6 th at 8:00 AM ET. A live webcast of the event will be... Read More

WALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will take part in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023 at 11:30 AM... Read More

Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis Greater than $730 million in cash and equivalents at 6/30/23; extended cash runway into second half of 2027 New clinical trials of MORF-057 in Crohn’s disease and MORF-088 in myelofibrosis to begin in the first half of 2024 WALTHAM, Mass., Aug.... Read More

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the Jefferies Healthcare Conference, including a hosted fireside chat, on Wednesday, June 7, 2023. Fireside Chat Information Date: Wednesday June 7,... Read More

WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023. Fireside Chat Information Date: Wednesday May... Read More

WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous findings and add new support to mechanistic understanding of the molecule’s activity in a nonhuman primate (NHP) model of ulcerative colitis. The poster presentation was made at Digestive Disease Week (DDW) 2023.... Read More

WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the closing of an underwritten public offering of 6,133,334 shares of its common stock at a price to the public of $45.00 per share, which includes 800,000 shares sold upon full exercise of the... Read More

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an underwritten public offering of 5,333,334 shares of its common stock at a price to the public of $45.00 per share. The gross proceeds from this offering are expected to be... Read More

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today announced a proposed underwritten public offering of its common stock. In addition, Morphic intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common... Read More

In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed EMERALD-2 Phase 2b Trial of MORF-057 progressing on track Ended first quarter 2023 with $421 million in cash, cash equivalents, and marketable securities, extending runway into second half of 2026 WALTHAM,... Read More

MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score MORF-057 achieves 25.7% clinical remission by Modified Mayo Clinic Score (mMCS) MORF-057 generally well tolerated with no safety signal observed MORF-057 achieves saturation of α4β7 receptor and demonstrates changes in α4β7 lymphocyte subsets that are consistent with Phase... Read More

WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss topline results from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative... Read More

WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care... Read More

Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23 Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic... Read More

WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink Global Healthcare conference including a hosted fireside chat. Presentation Information 8:40 AM ET, Thursday February 16, 2023... Read More

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST. A live webcast of... Read More